Generic Drugs Market Forecast 2016-2026

LONDON, May 9, 2016 /PRNewswire/ —

What can be expected from the Generic Drugs Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.
Our 306-page report provides 175 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across all the major regional and national generic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.

See detailed profiles or revenue forecasts for some of the leading regions in the generic drugs market
• US
• EU5
• Emerging markets

See revenue forecasts for the leading international markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets, including:
• US
• UK
South Korea

To see a report overview please email Sara Peerun on

Leading companies and potential for market growth
Visiongain forecasts overall revenue for the Generic Drugs Market will reach $254.6bn in 2016. We predict a high revenue growth over the forecast period driven by an ageing population, healthcare cost saving strategies and rapid growth of emerging economies.

Our work analyses the key companies in the market. See visiongain‘s analysis of ten leading companies, including:
• Teva
Novartis (Sandoz)
• Allergan
• Mylan
• Pfizer
• Abbott
• Sun Pharma
• Fresenius Kabi
• Sanofi

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Generic drugs revenue and share of total revenue
• Historic revenue (where available), analysis and discussion of company performance
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the generic drugs industry?
Our new report discusses issues and events affecting the generic drugs market. You will find discussions, including qualitative analyses:
• Highly fragmented and competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future generic drug opportunities

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets report helps you
In summary, our 306-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Generic Drugs market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for major regional markets – US, EU5, Asia-Pacific, Emerging markets
• Revenue forecasts to 2026 for fourteen leading national markets – US, Germany, UK, France, Italy, Spain, China, Japan, India, Brazil, Russia, Mexico, South Korea and Turkey
• Assessment of leading companies – analysis of products, revenue (where available), mergers & acquisitions, and pipelines
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain‘s study is for everybody needing commercial analyses for the generic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.

To see a report overview please email Sara Peerun on

To request an exec summary of this report please email Sara Peerun at or call Tel: +44 (0) 20 7336 6100

Or click on

Companies Mentioned in the Report 




Alcon (Novartis)

Allergan (Actavis)


Anda Inc

APP Pharmaceuticals

Arrow Group (Actavis)

Ascent Pharmahealth (Actavis)

ASKA Pharmaceuticals



Bergamo (Amgen)

Bioniche Pharma (Mylan)

BMP Sunstone (Sanofi)

CFR Pharmaceuticals (Abbott)


Dabur Pharma (Fresenius Kabi)

Daiichi Sankyo

Dalim BioTech

Dr Reddy’s Laboratory

Ebewe Pharma (Novartis)

Eden Biopharm Group


Elder Pharmaceuticals (Torrent Pharmaceuticals)

Eli Lilly

Elyson Pharmaceuticals

EMS Sigma Pharma

Eurofarma Laboratories

Farmacias Similares

Fenwal (Fresenius Kabi)

Forest Laboratories (Actavis)

Foshan Chanbende Development

Fougera Pharmaceuticals (Novartis)

Fresenius Kabi

Fresenius SE & Co

Fuji Pharma

Gedeon Richter

Genfar S.A (Sanofi)

Genzyme (Sanofi)

Gilead Sciences

GlaxoSmithKline (GSK)

Greenstone (Pfizer)

Grupo Sanborns

Grupo Uriach

Hospira (Pfizer)

IDEV Technologies (Abbott)

Ilsung Pharmaceuticals

InnoPharma Inc

Itero Biopharmaceuticals


Javelin Pharmaceuticals (Hospira)


KMS Pharmaceutical

Kowa Pharmaceuticals


Labesfal Genéricos (Fresenius Kabi)

Laboratorio Sanderson (Fresenius Kabi)

Laboratorios Best

Laboratorios Kendrick (Sanofi)

Lek (Novartis)


Mayne Pharma (Hospira)

Medley (Sanofi)

Merck KGaA

MN Pharma (Amgen)

Momenta Pharmaceuticals


Natco Pharma

Nexus Pharmaceuticals


Nippon Chemiphar

Novartis (Sandoz)

Novo Nordisk

OptiMedica (Abbott)

Orchid Chemicals & Pharmaceuticals

Oriel Therapeutics (Novartis)

Parenteral Drugs India Ltd



Piramal (Abbott Laboratories)

Pliva (Teva)

PT Soho Global Health

Ranbaxy (Sun Pharmaceuticals)



Sabex (Novartis)


Sawai Pharmaceuticals

Schein Pharmaceutical (Actavis)

Shelys (Aspen)

Sigma Pharmaceuticals (Aspen)

Solvay Pharmaceuticals (Abbott)

Specifar Pharmaceuticals (Actavis)

STADA Arzneimittel

Sun Pharma



Taiyo Pharmaceuticals

Teuto Brasileiro (Pfizer)


The Laboratory Of Analytical Services International Ltd


UDL Laboratories

Uteron Pharma (Actavis)

Valeant Pharmaceuticals


Warner Chilcott (Actavis)


Wyeth (Pfizer)

Zentiva (Sanofi)

Zhejiang Chiral Medicine Chemicals Co. Ltd

Zhejiang Hisun Pharmaceutical

Zydus Cadila

Organisations Mentioned in the Report 

Assogenerici [Italy]

Blue Cross Blue Shield Association (BCBSA) [US]

British Generic Manufacturers Association (BGMA)

Caisse Nationale de l’Assurance Maladie (CNAM) [France]

Center for Drug Evaluation and Research (CDER) [US]

Centers for Medicare and Medicaid Services [US]

China Food and Drug Administration (CFDA)


Competion and Markets Authority (CMA) [UK]

Congressional Budget Office (CBO) [US]

European Commission

European Generics Medicines Association (EGA)

European Medicines Agency (EMA)

European Patent Office (EPO)

Federal Trade Commission (FTC) [US]

Federal Commission for the Protection against Sanitary Risk (COFEPRIS)

Food and Drugs Administration (FDA) [US]

Gesund-heits-bericht-erstat-tung des Bundes (Federal Health Monitoring System, Germany)

General Adminsistratioon of Quality Supervision, Inspection and Quarantine (AQSIQ) [China]

General Directorate of Pharmaceuticals and Pharmacy (GDPP) [Turkey]

Medicine and Healthcare products Regulatory Agency (MHRA)

Ministry of Health, Labour and Welfare (MHLW) [Japan]

Ministry of Human Resources and Social Security (MOHRSS)

National Development and Reform Commission (NDRC)

National Health Service (NHS)

National Pharmaceutical Pricing Authority [India]

Pan American Health Organization (PAHO)

Pharmaceutical and Medical Devices Agency (PMDA) [Japan]

Queen Mary University of London

Servicio Sanitario Nazionale (SSN) [Italy]

United Nations’ Department of Economic and Social Affairs

US Generic Pharmaceutical Association (GPhA)

Veropharm (Abbott)

World Health Organization (WHO)

World Trade Organisation (WTO)

To see a report overview please email Sara Peerun on

Leave a Reply